These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39340215)

  • 1. Yap methylation-induced FGL1 expression suppresses anti-tumor immunity and promotes tumor progression in KRAS-driven lung adenocarcinoma.
    Jiang J; Ye P; Sun N; Zhu W; Yang M; Yu M; Yu J; Zhang H; Gao Z; Zhang N; Guo S; Ji Y; Li S; Zhang C; Miao S; Chai M; Liu W; An Y; Hong J; Wei W; Zhang S; Qiu H
    Cancer Commun (Lond); 2024 Nov; 44(11):1350-1373. PubMed ID: 39340215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. m
    Wu J; Yi T; Zhuo C; Wang D; Zhang M; Hu R; Wu D; Hou G; Xing Y
    J Cell Physiol; 2024 May; 239(5):e31220. PubMed ID: 38372068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
    Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1-FGL1-MYH9 axis.
    Tang XY; Xiong YL; Zhao YB; Yang J; Shi AP; Zheng KF; Liu YJ; Shu C; Jiang T; Ma N; Zhao JB
    Front Immunol; 2022; 13():1014053. PubMed ID: 36268014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STC1 competitively binding βPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop.
    Ren Z; Xu Z; Chang X; Liu J; Xiao W
    Pharmacol Res; 2024 Jun; 204():107218. PubMed ID: 38768671
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
    Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer.
    Boumelha J; de Castro A; Bah N; Cha H; de Carné Trécesson S; Rana S; Tomaschko M; Anastasiou P; Mugarza E; Moore C; Goldstone R; East P; Litchfield K; Lee SH; Molina-Arcas M; Downward J
    Cancer Res; 2024 Jul; 84(14):2231-2246. PubMed ID: 38635884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma.
    Xu T; Fang Y; Gu Y; Xu D; Hu T; Yu T; Xu YY; Shen HY; Ma P; Shu Y
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39384195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eicosapentaenoic Acid Inhibits
    Chiu CF; Hsu MI; Yeh HY; Park JM; Shen YS; Tung TH; Huang JJ; Wu HT; Huang SY
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33801246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
    Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J
    Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903
    [No Abstract]   [Full Text] [Related]  

  • 13. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
    Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
    Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma.
    Zhang X; Yu K; Ma L; Qian Z; Tian X; Miao Y; Niu Y; Xu X; Guo S; Yang Y; Wang Z; Xue X; Gu C; Fang W; Sun J; Yu Y; Wang J
    Theranostics; 2021; 11(12):5650-5674. PubMed ID: 33897873
    [No Abstract]   [Full Text] [Related]  

  • 17. HES6 Mediates Oxidative Phosphorylation Pathway to Promote Immune Infiltration of CD8 + T Cells in Lung Adenocarcinoma.
    Chen Z; Wang Y; Tang W; Xu S; Yu H; Chen Z
    J Immunother; 2024 Oct; 47(8):313-322. PubMed ID: 39005046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACADL suppresses PD-L1 expression to prevent cancer immune evasion by targeting Hippo/YAP signaling in lung adenocarcinoma.
    Li L; Wang LL; Wang TL; Zheng FM
    Med Oncol; 2023 Mar; 40(4):118. PubMed ID: 36929466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
    Yang P; He S; Ye L; Weng H
    Int Arch Allergy Immunol; 2024; 185(9):910-920. PubMed ID: 38781935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival.
    Nikou S; Arbi M; Dimitrakopoulos FD; Sirinian C; Chadla P; Pappa I; Ntaliarda G; Stathopoulos GT; Papadaki H; Zolota V; Lygerou Z; Kalofonos HP; Bravou V
    J Mol Histol; 2020 Aug; 51(4):385-400. PubMed ID: 32592097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.